Imaging on Lung Cancer and Treatment with Targeted Therapy.

Girish S Shroff, Marcelo F Benveniste, Patricia M de Groot, Brett W Carter, Carol C Wu, Chitra Viswanathan, Mylene T Truong

Journal: Seminars in ultrasound, CT, and MR 2018;39(3):308-313

PMID: 29807641

Full Text on Elsevier Science View on PubMed

Abstract

The identification of genetic mutations known as oncogenic driver mutations that lead to the growth and survival of cancer cells has been an important advance in the field of oncology. Treatment in advanced non-small-cell lung cancer (NSCLC) has transitioned from a more general approach to a more personalized approach based on genetic mutations of the cancer itself. Common mutations detected in patients with advanced NSCLC include mutations of epidermal growth factor receptor and anaplastic lymphoma kinase (ALK). Targeted therapies are aimed at the products of these gene mutations and include erlotinib (used in epidermal growth factor receptor mutant NSCLC) and crizotinib (used in anaplastic lymphoma kinase positive NSCLC). In this review, we discuss common genetic mutations in advanced NSCLC, the role of targeted therapies, and imaging findings that can be associated with various genetic mutations.

Address: Department of Diagnostic Radiology, University of Texas M. D. Anderson Cancer Center, Houston, TX. Electronic address: [email protected].; Department of Diagnostic Radiology, University of Texas M. D. Anderson Cancer Center, Houston, TX.

DOI: 10.1053/j.sult.2018.02.003